Results 171 to 180 of about 270,928 (312)

Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance. [PDF]

Drug Dev Res
Liao R, Luo M, Yang F, Xu L, Zhang J, Zhang W, Guan S, Zhang Y, Luo P, Cheng P, Yang J, Li Y, Wang Q.   +12 more
europepmc   +1 more source

Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro

Advanced Science, EarlyView.
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel, Anna‐Sophie Schlemmer, Andrea W. Eiken, Zachary W. Wagoner, Dennis Vöhringer, Lena Christ, Alex Dulovic, Patrick Marsall, Madeleine Fandrich, Eduardo J. S. Brás, Julia Marzi, Friederike Bärhold, Julia Philipp, Sven Becker, Lisa E. Wagar, Peter Loskill   +15 more
wiley   +1 more source

Immunomagnetic Sample Preparation Targeting Host- and Viral-Derived Antigens for HIV-1 Isolation from Limited Plasma Volumes. [PDF]

Anal Chem
Gulati GK, Panpradist N, Lutz BR, Lai JJ.   +3 more
europepmc   +1 more source

Machine‐Learning Microfluidic Minute‐Scale Microorganism Metrics Monitoring(M6)

Advanced Science, EarlyView.
ABSTRACT On‐site monitoring of microorganisms remains challenging because of low concentrations, strong background interference, and dynamic aerosol diffusion, particularly for aerosol‐transmitted pathogens. Here, we report a rapid detection platform that integrates a Puri‐focusing microfluidic chip, electrochemical impedance spectroscopy (EIS), and ...
Ning Yang, Jiahao Ding, Si Chen, Lijie Yan, Shichao Ding, Lavonda Li, Junyi Sun, Haodong Liu, Tongge Li, Ning Liu, Mingji Wei, Xiaoyong Zhu, Xiaobo Zou, Shouqi Yuan, Xingcai Zhang   +14 more
wiley   +1 more source

CircRNA based bi-antigen vaccines against mpox virus induce potent and durable cross-protection in mice. [PDF]

Mol Biomed
Zhou J, Wang C, Wu Y, Zhao B, Yang Y, Ye T, Zhang K, Li F, Hu J, Zhang K, Liu F, Wang W, Wang C, Wang Z, Chuai X, Chiu S.   +15 more
europepmc   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Co-occurrence of viral encephalitis and autoimmune encephalitis: overlapping peaks encephalitis or coincidence condition? [PDF]

BMC Neurol
Chen H, Shi X, Huang Z, Li X, Zhou Y, Tan D, Xie Z, Wu X, Zhou M, Hong D.   +9 more
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy. [PDF]

Curr Heart Fail Rep
Goli N, Wilcox J, Barnard J, Tang WHW.
europepmc   +1 more source

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Advanced Science, EarlyView.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee, Chul‐Gyun Lim, Pothiappan Vairaprakash, Jong‐Min Kim, Jiyoon Kim, Ji‐Young Park, Klaus M. Hahn, Hyunbo Shim, Hae Woong Choi, Tobias S. Ulmer, Soon Jun Hong, Chungho Kim   +11 more
wiley   +1 more source